InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 421 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR Surprise! Financial Assistance To Help With Your Medical Bills May Be... December 20, 2023 Gift Giving During a Pandemic December 3, 2020 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... June 20, 2025 Pattern of DNA Damage Links Colorectal Cancer and Diet High in... July 22, 2021 Load more HOT NEWS “Things Are Shrinking” Says Olivia Newton-John About Her Stage IV Breast... Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations 癌症治疗期间如何保证日常活动的安全和独立执行 Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients...
